Evercore ISI lowered the firm’s price target on Penumbra (PEN) to $345 from $360 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- FTC issued Second Request to Penumbra, Boston Scientific over merger review
- Private Markets: Kraken pauses IPO plans, Quince raises $500M
- Hold Rating Maintained on Penumbra Amid Strong Results but Limited Visibility Ahead of Boston Scientific Acquisition
- Penumbra price target raised to $360 from $340 at Evercore ISI
- Penumbra trading resumes